{"created":"2023-07-27T06:51:20.244303+00:00","id":44723,"links":{},"metadata":{"_buckets":{"deposit":"14c379d1-ce17-4341-b13b-99ad136854b6"},"_deposit":{"created_by":18,"id":"44723","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"44723"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00044723","sets":["2812:2813:2827"]},"author_link":["310","69907"],"item_9_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2007-04","bibliographicIssueDateType":"Issued"},"bibliographicPageStart":"3p.","bibliographicVolumeNumber":"2005-2006","bibliographic_titles":[{"bibliographic_title":"平成18(2006)年度 科学研究費補助金 基盤研究(C) 研究成果報告書"},{"bibliographic_title":"2006 Fiscal Year Final Research Report","bibliographic_titleLang":"en"}]}]},"item_9_creator_33":{"attribute_name":"著者別表示","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{}],"nameIdentifiers":[{},{}]}]},"item_9_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"(1)臨床例における腹膜転移(再発)の早期診断\n腹膜播種が確定している症例において血清IV型コラーゲン値は全例高値であったが、腹膜再発や再燃の過程において画像診断や臨床症状、既存の血清腫瘍マーカーと比較し、早期診断に有用かどうかを検討した。現在、腹膜転移を有する13症例を追跡しているが、いずれの症例においても症状の進行とともに血清IV型コラーゲン値は上昇している。また、画像診断や臨床症状、腫瘍マーカーの上昇が明確でない腹膜再発高危険症群のなかに血清IV型コラーゲン値の上昇してきた症例が5例存在しており、うち3例は腹腔鏡検査において腹膜再発と診断された。残り2例はcut off値付近を推移しており経過観察中である。\n(2)胃癌細胞株における検討\n胃癌におけるアンギオテンシン1型受容体についての検討\nIn vitroにおいてヒト胃癌細胞株5株中4株にアンギオテンシン1型受容体(AT1)が発現しており、アンギオテンシンIIの添加によりその増殖率は亢進した。また、この増殖率亢進はAT1の拮抗剤であるcandesartanにより抑制された。このAT1を介した増殖率亢進の機序は、ERKのリン酸化に伴う増殖シグナルおよびNF-kBの活性化に伴うsurvivinの誘導による抗アポトーシス効果であることを証明した。\nヌードマウスに高度腹膜転移株OCUM-2MD3を1x107個腹腔内投与したところ、移植4週目には癌性腹水を伴う腹膜播種が形成されたが、組織学的には腫瘍の線維化はそれほど顕著ではなかった。そこで、AT1を介した臓器の線維化についての検討は断念し、AT1を介した腫瘍増殖に対する分子標的治療の可能性についてin vivoで検討した。移植1週間後からcandesartan 10mg/kgを連日経口投与した群はコントロール群と比較し、有意に生存率の延長を認めた。\n以上より、胃癌腹膜転移の早期診断に血清IV型コラーゲン値測定が有用である可能性が示された。また、胃癌の増殖および線維化にはAT1を介する経路が存在し、その拮抗剤であるcandesartan(ブロプレス:降圧剤)をもちいた分子標的治療の可能性が示された。","subitem_description_type":"Abstract"},{"subitem_description":"Evaluation of the serum type IV collagen for early diagnosis of peritoneal metastases (recurrence)\nThe purpose of this study is to determine whether the type IV collagen, which is marker of hepatic fibrosis, could be useful biomarker for peritoneal metastasis. Type IV collagen was measured in 112 patients who were diagnosed wit gastric cancer : early cancer 55 (Group A), advanced cancer 43 (Group B), patients with peritoneal metastasis 27 (Group C). And they were compared with conventional biomarker (CEA, CA19-9, CAl25). The median type IV collagen levels in Group C was significantly higher than Group A and B (p<0.0001). In the clinical course of 13 patients with peritoneal metastasis, all of the serum type IV collagen levels were increasing according to their tumor progression. Furthermore, 3 of 5 patients, who were in the high risk group for peritoneal recurrence, were found peritoneal recurrence by laparoscopy without clinical, radiological, biochemical symptoms. These findings sugge st that the serum type IV collagen is a useful marker for early diagnosis of peritoneal metastasis with gastric cancer.4\nAngiotensin II activates MAP kinase and NF-kB through angiotensin II type I receptor in gastric cancer cells\nFour of 5 gastric cancer cell lines were found angiotensis II type 1 (AT1) receptor expression using western blot analysis. Angiotensin II stimulated growth of AT1 positive gastric cancer cell and this proliferative response was inhibited by candesartan, a specific AT1 receptor antagonist. Angiotensin II plays a role in the growth of AT1 positive gastric cancer cells through MAP kinase activation by ERK1/2 phosphorylation and surviving induction as antiapoptotic molecule by NF-kB activation.\nOne of the AT1 receptor expressing cell lines, OCUM2MD3, which had a very high peritoneal metastatic potential, was used as in vivo experiment. OCUM2MD3 made peritoneal metastasis including massive ascites and metastatic nodules 4weeks after intraperitoneal injection of 1×107 cells in nude mice. To elucidate whether over-expression of AT1 correlate to tumor progression, AT1 receptor antagonist, candesartan, has been treated everyday from 1 week after tumor injection. The candesartan group showed a significant longer survival than control group. These finding suggest that AT1 activation correlates tumor progression and its receptor antagonist may be a candidate for the molecule targeting therapy.","subitem_description_type":"Abstract"}]},"item_9_description_22":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究課題/領域番号:17591383, 研究期間(年度):2005-2006","subitem_description_type":"Other"},{"subitem_description":"出典：「胃癌腹膜転移における診断法の開発とアンギオテンシン系を介した線維化機構とその制御」研究成果報告書　課題番号17591383\n  (KAKEN：科学研究費助成事業データベース（国立情報学研究所）)\n　　　本文データは著者版報告書より作成","subitem_description_type":"Other"}]},"item_9_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.24517/00051064","subitem_identifier_reg_type":"JaLC"}]},"item_9_publisher_17":{"attribute_name":"公開者","attribute_value_mlt":[{"subitem_publisher":"金沢大学医薬保健研究域医学系"}]},"item_9_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/search/?qm=10301194"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/search/?qm=10301194","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-17591383/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-17591383/","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-17591383/175913832006kenkyu_seika_hokoku_gaiyo/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-17591383/175913832006kenkyu_seika_hokoku_gaiyo/","subitem_relation_type_select":"URI"}}]},"item_9_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-06-14"}],"displaytype":"detail","filename":"ME-PR-FUSHIDA-Y-kaken 2007-3p.pdf","filesize":[{"value":"114.0 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"ME-PR-FUSHIDA-Y-kaken 2007-3p.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/44723/files/ME-PR-FUSHIDA-Y-kaken 2007-3p.pdf"},"version_id":"1e7c4841-e10f-4f95-b333-2ec7130ab67e"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"胃癌腹膜転移における診断法の開発とアンギオテンシン系を介した線維化機構とその制御","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"胃癌腹膜転移における診断法の開発とアンギオテンシン系を介した線維化機構とその制御"},{"subitem_title":"The development of early diagnostic marker for peritoneal metastasis, and the management of tumor fibrosis through angiotensin II type I (AT1) receptor in gastric cancer","subitem_title_language":"en"}]},"item_type_id":"9","owner":"18","path":["2827"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-06-14"},"publish_date":"2018-06-14","publish_status":"0","recid":"44723","relation_version_is_last":true,"title":["胃癌腹膜転移における診断法の開発とアンギオテンシン系を介した線維化機構とその制御"],"weko_creator_id":"18","weko_shared_id":-1},"updated":"2023-07-27T14:34:11.888046+00:00"}